Basic Eldepryl Information

• INN (International Nonproprietary Name): Selegiline.
• Brand Names Available In United Kingdom: Eldepryl — tablets 5 mg and 10 mg in blister packs of 28 or 100.
• ATC Code: N04BD01.
• Forms & Dosages: Tablet 5 mg and 10 mg in blisters (28, 100); capsule 5 mg; orally disintegrating tablet 1.25 mg (Zelapar); transdermal patch 6, 9, 12 mg/24 hr (Emsam).
• Manufacturers In United Kingdom: Sovereign Medical.
• Registration Status In United Kingdom: Prescription only; approved by MHRA.
• OTC / Rx Classification: Prescription only (Rx) in the UK and EU.

Latest Research Highlights UK & EU 2022–2025

What Has Recent Real‑World Research Shown About Selegiline?

Multiple observational NHS cohort analyses and regional registry studies across the UK and EU between 2022 and 2025 report modest benefits when selegiline is used as an adjunct to levodopa.

Those reports describe small‑to‑moderate increases in patient "on" time and a delayed need to escalate levodopa doses.

Effect sizes are heterogeneous across studies and patient groups, with variation by age and baseline disease severity.

Safety surveillance summaries from MHRA Yellow Card reports and EU pharmacovigilance note predictable adverse reactions such as nausea, insomnia and orthostatic hypotension.

Rare serious events such as hypertensive crises or serotonergic reactions have been reported when selegiline is combined with contraindicated medicines.

Comparative real‑world analyses in Europe contrast selegiline with rasagiline and safinamide and find newer agents may offer similar or slightly improved tolerability for some patients.

Cost, local formulary decisions and individual response remain key drivers for prescribing choices within NHS practice.

Top Takeaways:

• Selegiline as adjunct can modestly increase "on" time but results vary between studies.
• Safety profile is predictable; monitor for nausea, insomnia and orthostatic hypotension.
• Newer MAO‑B agents may offer tolerability advantages for some patients, but cost and individual response matter.

Clinical Effectiveness In The UK

How Does Selegiline Perform In NHS Practice?

Selegiline (Eldepryl) is commonly used in NHS trusts and Parkinson’s specialist clinics as an early adjunct to levodopa to reduce motor fluctuations.

Many patients report reduced wearing‑off episodes and better daily mobility after starting selegiline.

Clinical audits within NHS settings show modest improvements in UPDRS motor scores and modest increases in patient‑reported "on" time, although improvements vary across age groups.

Safety observations in NHS cohorts mirror MHRA summaries with common reactions such as nausea, dizziness and insomnia reported most often.

Elderly patients on multiple medicines require closer monitoring due to fall risk and potential polypharmacy interactions.

Clinicians often advise slow titration and emphasise pharmacist counselling at community chains and hospital pharmacies before and during treatment.

Product Information Note: Eldepryl tablets are available in 5 mg and 10 mg strengths, with a typical regimen of 5–10 mg daily.

Definitions:

• UPDRS: Unified Parkinson's Disease Rating Scale.
• "On" Time: Periods when symptoms are well controlled by medication.
• Wearing‑Off: Return of Parkinsonian symptoms before the next dose of levodopa.

Indications And Expanded Uses

What Is Selegiline Approved For And How Is It Used In Practice?

Selegiline (INN selegiline) is authorised as a monoamine oxidase B (MAO‑B) inhibitor for Parkinson’s disease under ATC code N04BD01.

In routine NHS practice it is used as an adjunct to levodopa to ameliorate motor fluctuations and help delay levodopa dose escalation.

Transdermal MAO agents such as Emsam are available in other markets but are not branded for Parkinson’s in the UK.

Off‑label uses are uncommon in the UK but transdermal MAO preparations see use for depressive disorders in other jurisdictions.

Clinical Checklist Before Starting Selegiline:

• Confirm current medicines and avoid combining with other MAOIs, certain opioids and potent serotonergics.
• Check cardiovascular history and assess blood pressure.
• Counsel on tyramine risk with aged cheeses and cured meats.

Approved Uses vs Off‑Label Uses:

• Approved: Adjunctive therapy for Parkinson’s disease with levodopa/carbidopa.
• Off‑Label: Rare use in depression occurs with transdermal MAO agents outside the UK, not with Eldepryl tablets.

Regulatory Terms:

• MHRA: Medicines and Healthcare products Regulatory Agency.
• EMA: European Medicines Agency.
• ATC: Anatomical Therapeutic Chemical classification system.

Composition And Brand Landscape

What Brands And Formulations Are Available In The UK Market?

Active ingredient: selegiline (INN).

In the UK, Eldepryl is the primary brand supplied as tablets in 5 mg and 10 mg blister packs of 28 or 100 units.

Global alternatives include Zelapar (orally disintegrating tablet 1.25 mg) and transdermal patches such as Emsam in other markets.

Manufacturers and suppliers include Sovereign Medical in the UK and global suppliers such as Sun Pharma, Teva and Sandoz.

Data Highlight: ATC code N04BD01 and selegiline is prescription only across UK and EU.

Pharmacy Context: Eldepryl is supplied through Boots, LloydsPharmacy, hospital dispensaries and accredited online pharmacies using EPS where available.

Contraindications And Special Precautions

Who Should Not Take Selegiline And What Precautions Are Needed?

Absolute contraindications include known hypersensitivity to selegiline or excipients, concurrent use with other MAOIs, certain opioid analgesics such as meperidine and serotonergic agents, and pheochromocytoma.

Relative contraindications requiring close monitoring include peptic ulcer disease, severe cardiovascular disease, and psychosis or mania.

Patients should be counselled about tyramine‑rich foods which can precipitate hypertensive reactions.

Practical Advice For Patients:

• Avoid driving or operating heavy machinery until you know how selegiline affects you because of dizziness or orthostatic hypotension.
• Limit alcohol and avoid unsupervised herbal serotonergic supplements.
• Report severe headache, chest pain or sudden blood pressure changes immediately.

Monitoring Checklist For Pharmacists:

• Confirm current medicines via NHS Summary Care Record and pharmacy PMR.
• Check baseline blood pressure and reassess after initiation or dose change.
• Counsel elderly patients about fall risk and review for interacting prescriptions.

Report suspected adverse reactions through the MHRA Yellow Card scheme.

Dosage Guidelines NHS‑Recommended Regimens

What Doses Are Used In Parkinson’s And How Should They Be Adjusted?

Standard adult dosing for Parkinson’s disease is 5–10 mg daily, commonly prescribed as 5 mg twice daily for tablets or capsules.

Orally disintegrating tablets such as Zelapar are typically 1.25–2.5 mg once daily.

Selegiline is commonly used alongside levodopa/carbidopa; levodopa doses may need adjustment once selegiline is started.

Special Populations:

• Paediatric use is not established and is not recommended for children.
• Elderly patients should start at the lower end of the dosing range and be titrated carefully.
• Use with caution in hepatic or renal impairment and monitor clinically.

Practical Counselling Script: Confirm dose, advise morning and midday dosing to reduce insomnia risk and explain missed‑dose rules (take if remembered unless near next dose; do not double up).

Storage: Store below 25°C in original packaging and keep out of reach of children.

Overdose Signs: Severe hypertension, agitation, seizures; seek immediate medical attention.

Interactions Overview Foods Drugs MHRA Reports

Which Foods And Medicines Interact With Selegiline?

Tyramine‑rich foods such as aged cheeses and cured meats can precipitate hypertensive episodes, so dietary caution is advised.

Alcohol should be moderated and caffeine may exacerbate tremor or insomnia.

Absolute drug interactions include other MAOIs, certain opioids such as meperidine, and many serotonergic agents including SSRIs, SNRIs and tramadol due to serotonin syndrome risk.

Sympathomimetics like nasal decongestants may increase blood pressure when combined with selegiline.

MHRA Yellow Card reports specifically request reporting of suspected serotonin syndrome, severe hypertension or unusual psychiatric changes associated with selegiline use.

Always consult the Summary Of Product Characteristics before combining with other medicines.

Cultural Perceptions And Patient Habits

How Do UK Patients View Selegiline And How Does That Affect Use?

Many UK patients value pharmacist counselling and continuity of care through the NHS when starting a medicine such as selegiline.

Online forums such as Parkinson’s UK and Patient.info often contain patient discussions about insomnia or interaction worries.

Older patients commonly prefer established brands like Eldepryl and may be cautious about switching to newer agents.

Regional prescribing differences occur between England, Scotland, Wales and Northern Ireland because of local formularies and budget decisions.

Practical Patient Habits That Help:

• Keep a medication diary to log "on" and "off" periods and side effects.
• Bring all medicines to every pharmacy or clinic visit for a full interaction check.
• Use EPS and GP online services where available to manage repeat prescriptions and monitoring.

Short Paraphrased Forum Themes:

• "Does this make me sleep worse?" — insomnia is a common concern.
• "Will it stop my wearing‑off?" — improvements reported but vary by person.

Availability And Pricing Patterns In The UK Market

Where Can Patients Get Eldepryl And How Much Will It Cost?

Availability: Eldepryl tablets (5 mg, 10 mg) are dispensed via Boots, LloydsPharmacy, hospital pharmacies and accredited online pharmacies.

Prescriptions are required under normal regulations, and EPS is widely used in England for electronic repeat dispensing.

Pricing: Patients in England may pay the NHS prescription charge unless exempt, while prescriptions are free in Scotland, Wales and Northern Ireland, creating regional cost differences.

Private or out‑of‑pocket costs vary by pharmacy, brand and pack size, with generics from suppliers such as Sun Pharma or Teva generally cheaper than branded Eldepryl.

Supply Considerations: Check MHRA and wholesalers for current availability and any shortage notices before advising patients.

Steps To Obtain Via EPS:

1. Obtain a prescription from your GP or specialist.
2. Nominate your pharmacy on the EPS system.
3. Collect at the nominated pharmacy or arrange delivery where available.

Purchase Note: In our online pharmacy, eldepryl is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Prescribing Preferences

How Does Selegiline Compare With Rasagiline, Safinamide And COMT Inhibitors?

Rasagiline is another MAO‑B inhibitor with once‑daily dosing which may improve adherence and is often considered interchangeable depending on formulary decisions.

Safinamide is a reversible MAO‑B inhibitor with additional glutamatergic effects and may be preferred for particular motor fluctuation patterns or when switching is considered.

COMT inhibitors such as entacapone or tolcapone extend levodopa action via a different mechanism and are chosen based on symptom profile and tolerance.

Prescriber Checklist:

• Compare efficacy evidence for wearing‑off and "on" time.
• Consider dosing frequency and likely adherence.
• Assess interaction profiles and comorbidities.
• Factor local formulary cost to the NHS and patient preference.

Frequently Asked Questions

Q: Will Selegiline Reduce My Levodopa Dose?

A: Selegiline can modestly delay the need for higher levodopa doses and reduce wearing‑off for some patients, but individual responses vary.

Q: Can I Eat Cheese While Taking Selegiline?

A: Avoid large portions of aged or tyramine‑rich foods while on MAO agents; your pharmacist will advise which foods to limit.

Q: What If I Miss A Dose?

A: Take the missed dose as soon as you remember unless it is almost time for the next dose; do not double the dose.

Q: How Soon Will Side Effects Show?

A: Common side effects such as nausea, dizziness or insomnia often appear early in treatment; report severe hypertension or psychiatric changes to NHS 111 and consider an MHRA Yellow Card report.

Referral Resources:

• Parkinson’s UK for patient support and condition education.
• NHS online patient portal for prescription and monitoring queries.

Guidelines For Proper Use Pharmacist Counselling Checklist

What Should Pharmacists Cover When Dispensing Selegiline?

Opening Checks: Confirm the indication for Parkinson’s disease, current medicines via the NHS Summary Care Record and any allergies.

Key Counselling Points To Give The Patient:

• Dosage schedule: typically 5–10 mg daily; ODT options 1.25–2.5 mg once daily.
• Avoid other MAOIs, certain opioids and serotonergic drugs.
• Dietary tyramine caution and storage below 25°C in original pack.
• Missed‑dose advice and not to double up on doses.
• Warning signs: severe headache, stiff neck, acute BP rise, hallucinations.

Monitoring Plan:

• Arrange blood pressure checks after initiation and after dose changes.
• Assess fall risk in elderly patients and schedule medication reviews.
• Record counselling on the PMR and supply printed NHS leaflet and Parkinson’s UK information.

Example Counselling Script For Collection:

"These tablets are selegiline 5 mg.

Take one tablet in the morning and one at midday if prescribed twice daily.

Avoid taking the afternoon or evening dose if you find you cannot sleep.

If you start a new medicine, bring it into the pharmacy so we can check for interactions."

Delivery Across United Kingdom